Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2015-05-22 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4/A -
Director's Dealing
2015-05-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a Regulation FD Disclosure about a poster presentation at a medical congress, which is furnished as an exhibit. The document explicitly states that the information is being furnished and not filed, indicating it is a disclosure rather than a full report. The length is 3280 characters, which is short and consistent with an announcement rather than a full report. There is no detailed financial data or comprehensive report content. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-05-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 18, 2015. It includes a Regulation FD Disclosure about a presentation at a medical symposium and references presentation slides as an exhibit. The text explicitly states that the information is being furnished and shall not be deemed filed for certain regulatory purposes. The document is short (3163 characters) and primarily serves as an announcement of a presentation rather than the presentation itself or a detailed financial report. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-05-18 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-05-11 English
10-Q
Interim / Quarterly Report Q1 2015
2015-05-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 6, 2015, reporting the results of operations and financial condition for the quarter ended March 31, 2015. It mentions a press release and a conference call regarding these results. The document itself is a current report filing, not the full quarterly or annual report. It includes a press release as an exhibit but does not contain detailed financial statements or comprehensive analysis. The length is 3068 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS), as it is a general regulatory announcement of financial results and related events without the full financial data or detailed report content.
2015-05-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.